



RECEIVED
JUL 07 2003
TECH CENTER 16012900
VPI/001083

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : L. Helms
Group Art Unit : 1615
Applicants : Bhami Shenoy et al.
Application No. : 10/034,950 Confirmation No.: 9344
Filed : December 26, 2001
For : CRYSTALS OF WHOLE ANTIBODIES AND
FRAGMENTS THEREOF AND METHODS FOR
MAKING AND USING THEM

New York, New York
June 27, 2003

Hon. Commissioner
for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information Disclosure
Statement in the above-identified application. This
Statement is submitted:

- ☐ within three months of the application filing date;
- ☒ more than three months from the application filing date but before the mailing date of the first Office Action on the merits.

In accordance with 37 C.F.R. § 1.97, submission of
this Statement requires no fee. However, if for any reason
a fee is due, the Director is hereby authorized to charge

payment of any fees required in connection with this
Information Disclosure Statement to Deposit Account
No. 06-1075. A duplicate copy of this letter is transmitted
herewith.

Respectfully submitted,




Margaret A. Pierri (Reg. No. 30,709)
Attorney for Applicants
Andrew K. Holmes (Reg. No. 51,813)
Agent for Applicants
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020
Tel.: (212) 596-9000

I hereby certify that this
Correspondence is being
deposited with the U.S.
Postal Service as First
Class Mail in an envelope
Addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on

June 27, 2003

Lillian Garcia


Signature of Person Signing



VPI/00008

RECEIVED
JUL 07 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : L. Helms
Group Art Unit : 1615
Applicants : Bhami Shenoy et al.
Application No. : 10/034,950 Confirmation No.: 9344
Filed : December 26, 2001
For : CRYSTALS OF WHOLE ANTIBODIES AND
FRAGMENTS THEREOF AND METHODS FOR MAKING
AND USING THEM

New York, New York
June 27, 2003

Hon. Commissioner
for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants,
through their representatives, hereby make of record the
documents listed in the accompanying Form PTO-1449, enclosed
herewith in duplicate. Copies of these documents are enclosed.

UNITED STATES PATENTS

Johal, U.S. Patent 4,334,024 (6/8/82);
Bosch et al., U.S. Patent 5,510,118 (4/23/96);
Eckenhoff et al., U.S. Patent 5,904,935 (5/18/99);
Navia et al., U.S. Patent 6,011,001 (1/4/00);
Khalaf, U.S. Patent 6,042,824 (3/28/00); and
Margolin et al., U.S. Patent 6,140,475 (10/31/00).

FOREIGN APPLICATIONS

PCT Publication WO 91/09943, published July 11, 1991
PCT Publication WO 96/40049, published December 19, 1996
PCT Publication WO 99/55310, published November 4, 1999
PCT Publication WO 00/52150, published September 8, 2000

OTHER DOCUMENTS

Baselga et al., "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts," Cancer Res., Volume 58, pp. 2825-31 (1998).

Bertolini et al., Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma," Neoplasia, Volume 96, pp. 282-87 (2000).

Blanco et al., "Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants," Eur. J. Pharm. Biopharm. Volume 45, pp. 285-94 (1998).

Braden et al., "X-ray crystal structure of an anti-Buckminsterfullerene antibody Fab fragment: Biomolecular recognition of C₆₀," Proc. Natl. Acad. Sci. USA, Volume 97, pp. 12193-97 (2000).

Brange et al., "Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations," Pharm. Res., Volume 9, pp. 715-26 (1992).

Covaceuszach et al., "Purification, crystallization and preliminary X-ray analysis of the Fab fragment from MNAC13, a novel antagonistic anti-tyrosine kinase A receptor monoclonal antibody," Acta. Crystallogr. D. Biol. Crystallogr., Volume 57, pp. 1307-09 (2001).

Dong et al., "Secondary Structure of the Pentraxin Female Protein in Water Determined by Infrared Spectroscopy: Effects of Calcium and Phosphorylcholine," Biochemistry, Volume 31, pp. 9364-70 (1992).

Dong et al., "Infrared Spectroscopic Studies of Lyophilization- and Temperature-Induced Protein Aggregation," J. Pharm. Sci., Volume 84, pp. 415-24 (1995).

Harris et al., "Comparison of the conformations of two intact monoclonal antibodies with hinges," Immunol. Rev., Volume 163, pp. 35-43 (1998).

Harris et al., "Crystallographic Structure of an Intact IgG1 Monoclonal Antibody," J. Mol. Biol., Volume 275, pp. 861-872 (1998).

Ito, et al., "Crystallization and preliminary X-ray crystallographic studies on a Fab fragment of the mouse anti-human Fas monoclonal antibody HFE7A," Acta. Crystallogr. D. Biol. Crystallogr., Volume D57, pp. 1700-1702 (2001).

Kim et al., "Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4," Arthritis Res., Volume 2, pp. 293-302 (2000).

Küttner et al., "A phage library-derived single-chain Fv fragment in complex with turkey egg-white lysozyme: characterization, crystallization and preliminary X-ray analysis," Molecular Immunology, Volume 35, pp. 189-194 (1998).

Malfait et al., "Chronic Relapsing Homologous Collagen-Induced Arthritis in DBA/1 Mice as a Model for Testing Disease-Modifying and Remission-Inducing Therapies," Arthritis Rheum., Volume 44, pp. 1215-24 (2001).

McPherson, "Preliminary Analysis: Mounting and aligning procedures," in Preparation and Analysis of Protein

Crystals, pp. 214-27 (John Wiley & Sons Publishing) (1989).

Mylvaganam et al., "Structural Basis for the Binding of an Anti-cytochrome *c* Antibody to its Antigen: Crystal Structures of FabE8-Cytochrome *c* Complex to 1.8 Å Resolution and FabE8 to 2.26 Å Resolution," J. Mol. Biol., Volume 281, pp. 301-22 (1998).

Pekarek et al., "Double-walled polymer microspheres for controlled drug release," Nature, Volume 367, pp. 258-60 (1994).

Pichla et al. "The Crystal Structure of a Fab Fragment to the Melanoma-Associated GD2 Ganglioside," J. Struct. Biol., Volume 119, pp. 6-16 (1997).

Pietras et al., "Monoclonal Antibody to HER-2/*neu* Receptor Modulates Repair of Radiation-induced DNA Damage and Enhances Radiosensitivity of Human Breast Cancer Cells Overexpressing This Oncogene," Cancer Research, Volume 59, pp. 1347-1355 (1999).

Pikal et al., "Quantitative Crystallinity Determinations for β -Lactam Antibiotics by Solution Calorimetry: Correlations with Stability," J. Pharm. Sci., Volume 67, pp. 767-73 (1978).

Pikal et al., "The Stability of Insulin in Crystalline and Amorphous Solids: Observation of Greater Stability for the Amorphous Form," Pharm. Res., Volume 14, pp. 1379-87 (1997).

Rodgers, "Practical Cryocrystallography," Methods in Enzymology, Volume 276, pp. 183-203 (1997).

Saul et al., "Structure of the Fab fragment from F124, a monoclonal antibody specific for hepatitis B surface antigen," Acta. Crystallogr. D. Biol. Crystallogr., Volume D56, pp. 945-951 (2000).

Shenoy et al., "Stability of Crystalline Proteins,
Biotechnol. Bioeng., Volume 73, pp. 358-69 (2001).


Sohi et al., "Crystallization and Preliminary X-ray
Analysis of the Fab Fragment of a Human Monoclonal IgM
Rheumatoid Factor (2A2)," J. Mol. Biol., Volume 242,
pp. 706-08 (1994).

Sullivan et al., "Sustained release of progesterone and
estradiol from the SABER™ delivery system: In vitro and
in vivo release rates," Proceed. Int'l. Symp. Control.
Rel. Bioact. Mater., Volume 25, pp. 653-54 (1998).

Yoshino, "Treatment with an Anti-IL-4 Monoclonal
Antibody Blocks Suppression of Collagen-Induced
Arthritis in Mice by Oral Administration of Type II
Collagen," J. Immunol., Volume 160, pp. 3067-3071
(1998).

It is respectfully requested that the enclosed
documents be (1) fully considered by the Examiner during the
examination of this application; and (2) printed on any patent
which may issue on this application. Applicants request that a
copy of Form PTO-1449, as considered and initialed by the
Examiner, be returned with the next communication.

Respectfully submitted,




Margaret A. Pierri (Reg. No. 30,709)
Attorney for Applicants
Andrew K. Holmes (Reg. No. 51,813)
Agent for Applicants
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020
Tel.: (212) 596-9000

I hereby certify that this
Correspondence is being
deposited with the U.S.
Postal Service as First
Class Mail in an envelope
Addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on

June 27, 2003

Lillian Garcia



Signature of Person Signing

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
VPI/00-08APPLICATION
NO. 10/034,950INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Shenoy et al.CONF. NO.
9344FILING DATE
December 26, 2001GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,334,024	6/8/82	Johal	435	232	
	5,510,118	4/23/96	Bosch et al.	424	489	
	5,904,935	5/18/99	Eckenhoff et al.	424	489	
	6,011,001	1/4/00	Navia et al.	514	2	
	6,042,824	3/28/00	Khalaf	424	94.6	
	6,140,475	10/31/00	Margolin et al.	530	402	

RECEIVED

JUL 07 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 91/09943	7/11/91	PCT	C12N	9/98		
	WO 96/40049	12/19/96	PCT	A61K	9/00		
	WO 99/55310	11/4/99	PCT	A61K	9/86		
	WO 00/52150	9/8/2000	PCT	C12N	7/00		


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Baselga et al., "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts," <u>Cancer Res</u> , Volume 58, pp. 2825-31 (1998).
	Bertolini et al., Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma," <u>Neoplasia</u> , Volume 96, pp. 282-87 (2000).
	Blanco et al., "Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants," <u>Eur. J. Pharm. Biopharm.</u> Volume 45, pp. 285-94 (1998).
	Braden et al., "X-ray crystal structure of an anti-Buckminsterfullerene antibody Fab fragment: Biomolecular recognition of C ₆₀ ," <u>Proc. Natl. Acad. Sci. USA</u> , Volume 97, pp. 12193-97 (2000).
	Brange et al., "Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations," <u>Pharm. Res.</u> , Volume 9, pp. 715-26 (1992).
	Covaceuszach et al., "Purification, crystallization and preliminary X-ray analysis of the Fab fragment from MNAC13, a novel antagonistic anti-tyrosine kinase A receptor monoclonal antibody," <u>Acta. Crystallogr. D. Biol. Crystallogr.</u> , Volume 57, pp. 1307-09 (2001).
	Dong et al., "Secondary Structure of the Pentraxin Female Protein in Water Determined by Infrared Spectroscopy: Effects of Calcium and Phosphorylcholine," <u>Biochemistry</u> , Volume 31, pp. 9364-70 (1992).
	Dong et al., "Infrared Spectroscopic Studies of Lyophilization- and Temperature-Induced Protein Aggregation," <u>J. Pharm. Sci.</u> , Volume 84, pp. 415-24 (1995).

JUL 07 2003

TECH CENTER 1600/2000

Sheet 2 of 3


 U.S. DEPARTMENT OF COMMERCE
 PATENT AND TRADEMARK OFFICE

 INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT

 ATTY. DOCKET NO.
 VPI/00-08

 APPLICATION
 NO. 10/034,950

 APPLICANT
 Shenoy et al.

 CONF. NO.
 9344


 FILING DATE
 December 26, 2001

 GROUP
 1615

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Harris et al., "Comparison of the conformations of two intact monoclonal antibodies with hinges," <u>Immunol. Rev.</u> , Volume 163, pp. 35-43 (1998).
	Harris et al., "Crystallographic Structure of an Intact IgG1 Monoclonal Antibody," <u>J. Mol. Biol.</u> , Volume 275, pp. 861-872 (1998).
	Ito, et al., "Crystallization and preliminary X-ray crystallographic studies on a Fab fragment of the mouse anti-human Fas monoclonal antibody HFE7A," <u>Acta. Crystallogr. D. Biol. Crystallogr.</u> , Volume D57, pp. 1700-1702 (2001).
	Kim et al., "Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4," <u>Arthritis Res.</u> , Volume 2, pp. 293-302 (2000).
	Küttner et al., "A phage library-derived single-chain Fv fragment in complex with turkey egg-white lysozyme: characterization, crystallization and preliminary X-ray analysis," <u>Molecular Immunology</u> , Volume 35, pp. 189-194 (1998).
	Malfait et al., "Chronic Relapsing Homologous Collagen-Induced Arthritis in DBA/1 Mice as a Model for Testing Disease-Modifying and Remission-Inducing Therapies," <u>Arthritis Rheum.</u> , Volume 44, pp. 1215-24 (2001).
	McPherson, "Preliminary Analysis: Mounting and aligning procedures," in <u>Preparation and Analysis of Protein Crystals</u> , pp. 214-27 (John Wiley & Sons Publishing) (1989).
	Mylvaganam et al., "Structural Basis for the Binding of an Anti-cytochrome c Antibody to its Antigen: Crystal Structures of FabE8-Cytochrome c Complex to 1.8 Å Resolution and FabE8 to 2.26 Å Resolution," <u>J. Mol. Biol.</u> , Volume 281, pp. 301-22(1998).
	Pekarek et al., "Double-walled polymer microspheres for controlled drug release," <u>Nature</u> , Volume 367, pp. 258-60 (1994).
	Pichla et al. "The Crystal Structure of a Fab Fragment to the Melanoma-Associated GD2 Ganglioside," <u>J. Struct. Biol.</u> , Volume 119, pp. 6-16 (1997).
	Pietras et al., "Monoclonal Antibody to HER-2/ <i>neu</i> Receptor Modulates Repair of Radiation-induced DNA Damage and Enhances Radiosensitivity of Human Breast Cancer Cells Overexpressing This Oncogene," <u>Cancer Research</u> , Volume 59, pp. 1347-1355 (1999).
	Pikal et al., "Quantitative Crystallinity Determinations for β -Lactam Antibiotics by Solution Calorimetry: Correlations with Stability," <u>J. Pharm. Sci.</u> , Volume 67, pp. 767-73 (1978).
	Pikal et al., "The Stability of Insulin in Crystalline and Amorphous Solids: Observation of Greater Stability for the Amorphous Form," <u>Pharm. Res.</u> , Volume 14, pp. 1379-87 (1997).
	Rodgers, "Practical Cryocrystallography," <u>Methods in Enzymology</u> , Volume 276, pp. 183-203 (1997).
	Saul et al., "Structure of the Fab fragment from F124, a monoclonal antibody specific for hepatitis B surface antigen," <u>Acta. Crystallogr. D. Biol. Crystallogr.</u> , Volume D56, pp. 945-951 (2000).
	Shenoy et al., "Stability of Crystalline Proteins," <u>Biotechnol. Bioeng.</u> , Volume 73, pp. 358-69 (2001).
	Sohi et al., "Crystallization and Preliminary X-ray Analysis of the Fab Fragment of a Human Monoclonal IgM Rheumatoid Factor (2A2)," <u>J. Mol. Biol.</u> , Volume 242, pp. 706-08 (1994).
	Sullivan et al., "Sustained release of progesterone and estradiol from the SABER™ delivery system: In vitro and in vivo release rates," <u>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.</u> , Volume 25, pp. 653-54 (1998).

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
VPI/00-08APPLICATION
NO. 10/034,950INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Shenoy et al.CONF. NO.
9344FILING DATE
December 26, 2001GROUP
1615

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Yoshino, "Treatment with an Anti-IL-4 Monoclonal Antibody Blocks Suppression of Collagen-Induced Arthritis in Mice by Oral Administration of Type II Collagen," <u>J. Immunol.</u> , Volume 160, pp. 3067-3071 (1998).